EUVIMEDEUVIMED entdecken
Open Access · CC BY-SA 4.0

DEVELOPMENT OF A RECOMBINANT VACCINE TO PREVENT INFLUENZA VIRUS INFECTION

Loso Judijanto, Aung Myint, Nandar Hlaing, Muntasir Muntasir

Journal of Biomedical and Techno Nanomaterials · 14.04.2025 · 2 (2) · 80-91

DOI: 10.70177/jbtn.v2i2.2025 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biomedical and Techno Nanomaterials, online erschienen am 14.04.2025. Verfasst von Loso Judijanto und 3 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-SA 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Influenza virus remains a significant global health challenge, causing seasonal epidemics and potential pandemics with high morbidity and mortality rates. This study aims to develop a recombinant vaccine as a safer and more effective alternative to traditional influenza vaccines, which often suffer from limited efficacy and lengthy production timelines. Utilizing a recombinant DNA technology approach, this research employed the baculovirus expression system to produce hemagglutinin (HA) antigens derived from the influenza A virus. Experimental methods included antigen purification, immunogenicity assays in murine models, and neutralizing antibody titration. Results revealed that the recombinant HA vaccine elicited a robust immune response, with a significant increase in hemagglutination inhibition titers compared to control groups. Furthermore, the vaccinated subjects exhibited substantial protection against viral challenge, evidenced by reduced viral load and minimized lung pathology. The findings suggest that recombinant vaccine platforms offer promising avenues for rapid and scalable vaccine development. This study underscores the potential of recombinant influenza vaccines in mitigating future influenza outbreaks with improved safety, efficacy, and production agility.

Zitieren

APA

Judijanto, L., Myint, A., Hlaing, N., & Muntasir, M. (2025). DEVELOPMENT OF A RECOMBINANT VACCINE TO PREVENT INFLUENZA VIRUS INFECTION. Journal of Biomedical and Techno Nanomaterials, 2(2), 80-91. https://doi.org/10.70177/jbtn.v2i2.2025

Vancouver

Judijanto L, Myint A, Hlaing N, Muntasir M. DEVELOPMENT OF A RECOMBINANT VACCINE TO PREVENT INFLUENZA VIRUS INFECTION. Journal of Biomedical and Techno Nanomaterials. 2025;2(2):80-91. doi:10.70177/jbtn.v2i2.2025

BibTeX
@article{Judijanto2025,
  author = {Judijanto, Loso and Myint, Aung and Hlaing, Nandar and Muntasir, Muntasir},
  title = {DEVELOPMENT OF A RECOMBINANT VACCINE TO PREVENT INFLUENZA VIRUS INFECTION},
  journal = {Journal of Biomedical and Techno Nanomaterials},
  year = {2025},
  volume = {2},
  number = {2},
  pages = {80--91},
  doi = {10.70177/jbtn.v2i2.2025}
}
Kostenlos starten →